Rula vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health marketplace connecting patients with in-network therapists and psychiatrists, Los Angeles CA, raised $65M+. Insurance-covered access in all 50 states.
About
Rula is a Los Angeles, California-based mental health marketplace founded in 2019 that connects patients with in-network licensed therapists and psychiatrists through an online directory and matching platform. The company has raised over $65 million and has built insurance coverage across all 50 US states, making it one of the broadest-access in-network therapy platforms in the country. Rula handles provider credentialing, insurance contracting, billing, and claims processing on behalf of its network clinicians.\n\nRula's marketplace allows patients to search for therapists and psychiatrists by specialty, insurance, location, language, and availability, with real-time availability shown and direct booking enabled. The platform is designed to reduce the common friction points in finding in-network mental health care: lengthy wait times, confusing insurance directory inaccuracies, and billing surprises. Rula verifies insurance eligibility before the first appointment and provides upfront cost estimates so patients know their expected out-of-pocket responsibility.\n\nThe company has focused heavily on therapist experience and provider satisfaction, offering competitive reimbursement rates, automated billing, flexible scheduling, and dedicated support to attract and retain high-quality clinicians. Rula competes with Headway, Alma, and Grow Therapy in the therapist marketplace and infrastructure segment. With its 50-state insurance footprint and consumer-friendly search experience, Rula is positioned as an accessible alternative to the fragmented and often outdated directories maintained by health plans.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.